We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$815M
AUM Growth
+$105M
Cap. Flow
+$27.8M
Cap. Flow %
3.41%
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
36
Reduced
33
Closed
18

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$22.9M
2
SDGR icon
Schrodinger
SDGR
+$16.6M
3
FTRE icon
Fortrea Holdings
FTRE
+$14.8M
4
OSCR icon
Oscar Health
OSCR
+$11.4M
5
HCA icon
HCA Healthcare
HCA
+$10.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
BSX icon
Boston Scientific
BSX
+$14.6M
3
KROS icon
Keros Therapeutics
KROS
+$10.8M
4
MTD icon
Mettler-Toledo International
MTD
+$9.1M
5
HUM icon
Humana
HUM
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Industrials 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.5M 1.41%
729,230
+168,205
+30% +$2.59M
DAWN
27
DELISTED
Day One Biopharmaceuticals
DAWN
$11.4M 1.4%
691,812
+66,063
+11% +$989K
BDX icon
28
Becton Dickinson
BDX
$50B
$11.3M 1.38%
45,597
-21,861
-32% -$5.23M
MNKD icon
29
MannKind Corp
MNKD
$1.24B
$10.9M 1.34%
2,405,936
-92,688
-4% -$364K
ACLX
30
DELISTED
Arcellx
ACLX
$10.9M 1.34%
156,598
-11,664
-7% -$740K
PCVX icon
31
Vaxcyte
PCVX
$8.88B
$10.2M 1.26%
149,956
-117,638
-44% -$8.15M
STRO icon
32
Sutro Biopharma
STRO
$353M
$10.1M 1.24%
179,005
+58,762
+49% +$2.6M
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.31B
$9.64M 1.18%
223,942
-70,846
-24% -$3.26M
TMO icon
34
Thermo Fisher Scientific
TMO
$223B
$9.05M 1.11%
15,572
+5,572
+56% +$3.13M
VRNA
35
DELISTED
Verona Pharma
VRNA
$8.52M 1.05%
529,520
+24,778
+5% +$428K
CSTL icon
36
Castle Biosciences
CSTL
$960M
$8.14M 1%
367,408
+10,252
+3% +$223K
LIVN icon
37
LivaNova
LIVN
$4.45B
$8.11M 1%
+145,000
New +$7.53M
ELV icon
38
Elevance Health
ELV
$86.6B
$7.86M 0.96%
+15,164
New +$7.54M
HAE icon
39
Haemonetics
HAE
$4.16B
$7.76M 0.95%
90,962
+21,022
+30% +$1.65M
TVTX icon
40
Travere Therapeutics
TVTX
$5.86B
$7.47M 0.92%
968,420
-50,392
-5% -$425K
IRWD icon
41
Ironwood Pharmaceuticals
IRWD
$714M
$7.4M 0.91%
850,000
+729,348
+605% +$8.85M
IRON icon
42
Disc Medicine
IRON
$3.09B
$6.7M 0.82%
107,593
+14,722
+16% +$955K
VTYX
43
DELISTED
Ventyx Biosciences
VTYX
$6.64M 0.82%
+1,208,099
New +$5.52M
AVDL
44
DELISTED
Avadel Pharmaceuticals
AVDL
$6.55M 0.8%
+387,770
New +$5.77M
TEVA icon
45
Teva Pharmaceuticals
TEVA
$42.8B
$6.4M 0.79%
+453,590
New +$5.72M
IONS icon
46
Ionis Pharmaceuticals
IONS
$9.39B
$6.13M 0.75%
141,499
-69,901
-33% -$3.33M
CVRX icon
47
CVRx
CVRX
$72.7M
$6.05M 0.74%
332,090
+92,090
+38% +$2.18M
NARI
48
DELISTED
Inari Medical, Inc. Common Stock
NARI
$6.01M 0.74%
+125,338
New +$6.7M
VCYT icon
49
Veracyte
VCYT
$3.59B
$5.63M 0.69%
254,092
+16,776
+7% +$409K
SLN
50
Silence Therapeutics
SLN
$641M
$5.28M 0.65%
244,471
+11,529
+5% +$251K
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Parkman Healthcare Partners held 117 positions worth $815M, up 15% from $710M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners deployed $27.8M of net new capital in Q1 2024, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was Eli Lilly: 32,117 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Boston Scientific, an estimated $14.6M trimmed.

  • Parkman Healthcare Partners's largest Q1 2024 buy was Eli Lilly: 32,117 shares worth $25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q1 2024, an estimated $16.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2024 reduction was Boston Scientific, cutting an estimated $14.6M.
  • Parkman Healthcare Partners fully exited Amgen in Q1 2024, selling an estimated $17.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $815M portfolio in Q1 2024.
  • Parkman Healthcare Partners opened 28 new positions and closed 18 in Q1 2024.
  • Parkman Healthcare Partners's portfolio value rose 15% quarter-over-quarter to $815M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2024, filed 15 May 2024.